Volume 2.43 | Nov 25

Prostate Cell News 2.43, November 25, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Estrogen Receptor β and 17β-Hydroxysteroid Dehydrogenase Type 6, a Growth Regulatory Pathway That Is Lost in Prostate Cancer
Researchers reveal that formation of 5α-androstane-3β,17β-diol via 17β-hydroxysteroid dehydrogenase type 6 from 5α-dihydrotestosterone is an important growth regulatory pathway that is lost in prostate cancer. [Proc Natl Acad Sci USA] Abstract

Watch the Video: Isolate Cells In As Little As 25 Minutes with EasySep™
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy
Here, researchers demonstrate that both normal mouse prostate tissue and human LuCaP35 prostate tumor explants display an epithelial-mesenchymal transition as well as increased stem cell-like features following androgen deprivation. [Cancer Res] Abstract

Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy
In this study, researchers offer a preclinical proof of concept in the TRAMP-C2 mouse model of prostate cancer that CTLA-4 blockade cooperates with cryoablation of a primary tumor to prevent the outgrowth of secondary tumors seeded by challenge at a distant site. [Cancer Res] Abstract

Lipid Nanoparticle siRNA Systems for Silencing the Androgen Receptor in Human Prostate Cancer In Vivo
In this study researchers investigated the ability of lipid nanoparticle (LNP) formulations of small interfering RNA (siRNA) to silence androgen receptor in human prostate tumor cell lines in vitro and in LNCaP xenograft tumors following intravenous injection. [Int J Cancer] Abstract

p65-Dependent Production of Interleukin-1β by Osteolytic Prostate Cancer Cells Causes an Induction of Chemokine Expression in Osteoblasts
Treatment of primary murine osteoblasts with conditioned medium of the human osteolytic prostate cancer cell line PC-3 results in a rapid induction of chemokine expression, thereby providing evidence for a molecular crosstalk between bone and tumor cells. The aim of this current study was to identify PC-3-derived molecules mediating this effect. [Cancer Lett] Abstract

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
The aim of this study was to develop an approach to assess the prevalence and function of androgen receptor variants in prostate cancer. [PLoS One] Abstract

LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through Heparin Binding-Epidermal Growth Factor Shedding and Epidermal Growth Factor Receptor-Mediated Extracellular Signal Regulated Kinase Signaling
Researchers characterized the mechanism by which LIV-1 drives human prostate cancer epithelial-to-mesenchymal transition in an androgen-refractory prostate cancer cells prostate cancer bone metastasis model. [PLoS One] Abstract

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
The objective of this study was to determine the role of immature cells in prostate cancer by analysis of the hepatocyte growth factor/c-MET pathway. [PLoS One] Abstract

A Possible Role for Perforin and Granzyme B in Resveratrol Enhanced Radiosensitivity of Prostate Cancer
In the present study, researchers established the constitutive expression of perforin and granzyme B by the PC-3 and DU145 prostate cancer cell lines with RT-PCR, IHC and/or Western blot. [J Androl] Abstract

CLINICAL RESEARCH

Circulating Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins (IGFBPs) in PSA-Detected Prostate Cancer: The Large Case Control Study ProtecT
Here scientists report the findings of a United Kingdom-based case-control study to investigate circulating IGFs and IGFBPs in prostate-specific antigen (PSA)-detected prostate cancer with regard to their potential associations with different cancer stages or grades. [Cancer Res] Abstract

Genetic Variation in Nucleotide Excision Repair Pathway Genes, Pesticide Exposure, and Prostate Cancer Risk
Researchers evaluated interactions between pesticide exposure and 324 single nucleotide polymorphisms tagging 27 nucleotide excision repair genes among 776 prostate cancer cases and 1,444 male controls in a nested case-control study of white Agricultural Health Study pesticide applicators. [Carcinogenesis] Abstract

Matched Cohort Analysis of Outcomes of Definitive Radiotherapy for Prostate Cancer in Human Immunodeficiency Virus-Positive Patients
The purpose of this study was to compare the biochemical outcome and toxicity scores of men with human immunodeficiency virus (HIV) and prostate cancer with a matched control population with negative or unknown HIV status when treated with external-beam radiotherapy. [Int J Radiat Oncol Biol Phys] Abstract

Spurious Elevation of Serum PSA after Curative Treatment for Prostate Cancer: Clinical Consequences and the Role of Heterophilic Antibodies
The aim of this study was to determine the prevalence of small, spurious PSA elevations, and the role of heterophilic antibodies. [Prostate Cancer Prostatic Dis] Abstract

Free Nature Immunology Webcast: HIV Vaccines

SCIENCE NEWS
Preliminary Data Demonstrate that 40 mg Daily Dose of Cabozantinib Yields a High Rate of Bone Scan Response in mCRPC
Exelixis, Inc. reported data from two ongoing clinical trials exploring lower starting doses of cabozantinib in cancer patients, including a phase I investigator-sponsored trial designed to assess the lowest effective dose of cabozantinib for treatment of metastatic bone lesions in patients with metastatic castration-resistant prostate cancer (mCRPC) as assessed by post-treatment changes in bone scans. [Press release from Exelixis, Inc. discussing research presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco] Press Release
INDUSTRY NEWS

First Patients Enrolled in Project to Improve NHS Cancer Gene Testing
Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the National Health Service (NHS) to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies. [Cancer Research UK] Press Release

Dendreon Announces the Centers for Medicare and Medicaid Services (CMS) Will Now Cover Infusion Costs Associated with the Administration of PROVENGE
Dendreon Corporation announced the CMS updated their coverage policy to now cover the infusion costs associated with the administration of PROVENGE®. [Dendreon Corporation] Press Release

Celgene Will Discontinue Phase III MAINSAIL® Trial in Castrate-Resistant Prostate Cancer
Celgene International Sàrl announced that based on the recommendation from the Data Monitoring Committee, it will discontinue its pivotal double-blinded Phase III MAINSAIL® trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer. [Business Wire] Press Release

MabCure Receives U$500,000.00 Licensing Fee As Well As 12.5% Ongoing Royalty for Its Prostate Cancer Diagnostic Technology
MabCure, Inc. announced that it has signed a license agreement with Biotech Investment Corp. This agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. [Business Wire] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW American Association for Cancer Research – Advances in Prostate Cancer Research
February 6-9, 2012
Orlando, United States

Visit our events page to see a complete list of events in the prostate cell community.
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit
here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us